Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia
NCT ID: NCT00939341
Last Updated: 2012-01-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
862 participants
INTERVENTIONAL
2009-07-31
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Investigate the Efficacy of Symbicort® SMART.
NCT00839800
Local Phase 4 Pan-European SMART Study
NCT00463866
Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy
NCT00319306
Asthma Control-A "Patient Follow up Programme" Maintenance and Reliever Therapy in a Single Inhaler
NCT00524641
Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia
NCT00576316
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Symbicort Turbuhaler 160/4.5 µg delivered dose
Symbicort (Budesonide/Formoterol)
Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Symbicort (Budesonide/Formoterol)
Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Asthma diagnosis at least 6 months before visit 1 of study
* Patients who have reversible airway obstruction continuous asthma treatment except Symbicort at least within 4 weeks before visit 1 of study
Exclusion Criteria
* Use of oral, rectal or parenteral glucocorticosteroids 30 days before visit 1 of study
* Smoking, current or previous with a smoking history of ≥ 10 pack years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guy Yeoman, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Guangzhou, Guangdong, China
Research Site
Zheng Ahou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Changsha, Hunan, China
Research Site
Qingdao, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Beijing, , China
Research Site
Chengdu, , China
Research Site
Fuzhou, , China
Research Site
Hangzhou, , China
Research Site
Nanjing, , China
Research Site
Shenyang, , China
Research Site
Zhengzhou, , China
Research Site
Hyderabad, Andhra Pradesh, India
Research Site
Ahmedabad, Gujarat, India
Research Site
Bangalore, Karnataka, India
Research Site
Bengaluru, Karnataka, India
Research Site
Indore, Madhya Pradesh, India
Research Site
Mumbai, Maharashtra, India
Research Site
Chennai, Tamil Nadu, India
Research Site
Coimbatore, Tamil Nadu, India
Research Site
Lucknow, Uttar Pradesh, India
Research Site
Noida, Uttar Pradesh, India
Research Site
Jakarta, DKI Jakarta, Indonesia
Research Site
Surabaya, East Java, Indonesia
Research Site
Chiayi City, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Bangkok, Bangkok, Thailand
Research Site
Pathumwan, Bangkok, Thailand
Research Site
Pathum Thani, Changwat Pathum Thani, Thailand
Research Site
Nakhonratchasima, Naimuang, Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lin J, Tang Y, Xiu Q, Kang J, Cai S, Huang K, Itoh Y, Ling X, Zhong N. Real-life effectiveness of budesonide/formoterol therapy in asthma: A subanalysis of the SMARTASIA study. Allergy Asthma Proc. 2016 Jan-Feb;37(1):27-34. doi: 10.2500/aap.2016.37.3910.
Zhong N, Lin J, Mehta P, Ngamjanyaporn P, Wu TC, Yunus F. Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study. BMC Pulm Med. 2013 Apr 4;13:22. doi: 10.1186/1471-2466-13-22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5890L00035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.